In this DNB//Back Bay Healthcare Capital Markets Episode, Vasilios Kofitsas, Partner and Managing Director at Back Bay Life Science Advisors speaks with Jim Cirenza and Kristoffer Braaten of DNB Bank in New York. They focus on key drivers affecting markets this year and discuss the recent news of the Fed’s decision to cut interest rates by 50-basis points.

Topics in the podcast include:

• After two difficult years, the appearance of a healthy market rotation since July
• The Fed’s decision mid-September to cut rates by 50 basis points
• Healthcare IPOs: historical and recent activity – is the window opening?
• An outlook including headwinds and tailwinds that may impact the healthcare sector

We welcome listener questions and/or topics you’d like to learn more about.

You can listen to previous episodes here or submit your inquiries here.

Learn more about the DNB//Back Bay Partnership and read our disclaimers at https://www.bblsa.com/dnb-back-bay-partnership.

After a summer away from podcasting, Back Bay Life Science Advisors’ Dr. Pete Bak and Christian Thienel are back on the mic to discuss current market dynamics in liver disease with a focus on one of the most closely watched space in hepatology, MASH.

The big news includes a rebrand from NASH (non-alcohol related steatohepatitis) to MASH (metabolic dysfunction-associated steatohepatitis), the FDA approval of Madrigal Pharmaceutical’s Rezdiffra and real-time court rulings in Europe that may affect the rate of play for Ocaliva, a drug used to treat adults with primary biliary cholangitis here in the US. As Christian mentions in this episode, “The path to success is not always a straight line.”

Other topics in this podcast include:

• Hepatology market dynamics over the past five years, including activity from Gilead, Novo Nordisk, Intercept and CymaBay
• How treatment for primary biliary cholangitis, an autoimmune condition, went from a one to a three-product market
• Payer monographs and what’s required for hepatology drugs
• The EMA recommendation earlier this month to revoke Ocaliva’s marketing authorization
• Which companies are active in the rare liver disease space and how they differentiate themselves

Thank you for listening. You can find previous episodes of the podcast here.

We’d love to hear from you. Ask questions and submit your feedback.

In this DNB//Back Bay Healthcare Capital Markets podcast episode, learn about the key considerations, mechanics and timelines of going public on a US exchange.

Topics in this podcast include:

• An overview of the decision-making process through execution for US-based and ex-US healthcare companies thinking about listing in the US
• Core considerations after deciding to pursue a US listing and how to prepare most effectively
• Building the “IPO advisory team”: types of advisors (legal, accounting, banking, IR firms, IP, etc.) and when to bring them in
• Key documents and associated timelines related to the SEC documentation as well as investor outreach
• What are the “don’ts” or mistakes companies make and how to avoid them

You can listen to previous episodes here or submit your inquiries here.

About our guests:

DNB//Back Bay is a committed partner throughout the healthcare development journey, addressing positioning, partnering, financing, M&A strategies, and listing support and execution on US and Nordic exchanges. Our team of more than 100 healthcare strategy and financial specialists spans the globe. Learn more about the DNB//Back Bay Partnership and read our disclaimers at https://www.bblsa.com/dnb-back-bay-partnership.

Cooley is among the top law firms for healthcare, tech and life science IPOs on both the issuer-side and underwriter-side. Their team of 1,300 lawyers is spread across 19 offices worldwide.